Open in app

After infection, Covid vaccine provides better protection against sickness: Lancet Studies.

Total Views:
Total Likes:
Published By:
Peeyush Ghalot
Published On:
(Image Courtesy: - Association of Psychological Science)

COVID 19 vaccination gives extra protection to those who have already been infected with SARS CoV-2, notably against severe disease, according to two new trials published in the Lancet. According to the first study, researchers discovered that four vaccines - including the Oxford AstraZeneca (ChAdOx1) vaccine, which is widely used in India as Covishield, CoronaVac, Janssen and Pfizer - BioNTech provide additional protection against symptomatic reinfection and severe outcomes such as hospitalization and death in people who have already had a SARS-CoV-2 infection.Over 22000 people took part in the study. CoronaVac had a 39 percent effectiveness against symptomatic reinfection among persons who had SARS CoV 2 infection and were later vaccinated, while Oxford-AstraZeneca had a 56 percent effectiveness, Janssen had a 44 percent effectiveness, and Pfizer-BioNTech had a 65 percent effectiveness. CoronaVac's effectiveness against hospitalization and mortality was 81 percent, Oxford-was AstraZeneca's 90 percent, Janssen's was 58 percent, and Pfizer-was BioNTech's 90 percent. All four vaccines have been shown to provide significant additional protection for people who have had a previous COVID 19 infection, lowering hospitalization and death rates. Vaccine benefits far outweigh any potential risk, according to study author Julio Croda of the Universidade Federal de Mato Grosso do Sul and Fundacao Universidade Federal de Mato Grosso do Sul, and support the case for vaccination, including the full vaccine series, among individuals with prior infection.

Reference: -